FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories

FDA
Sep.30
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.

Key Points

● Unified Form: FDA has merged Forms 3741 and 3741a into a redesigned Form FDA 3741 covering regulated categories including cigarettes, e-cigarettes, heated tobacco products and nicotine pouches.

● Current Scope: Existing establishment registration and product listing requirements remain limited to domestic tobacco product establishments.

● Foreign Manufacturers: FDA proposed in June to extend these requirements to foreign manufacturers, but the rule has not been finalized.

● Manufacturing Compliance: In 2Firsts’ view, recent developments point to greater FDA attention to manufacturing entities and product-level information.

 

2Firsts

WASHINGTON, Sept. 29, 2026

The U.S. Food and Drug Administration has introduced a redesigned tobacco product establishment registration and product listing form, combining two previously separate forms into a single form covering all regulated tobacco product categories.

The updated Form FDA 3741, launched on Sept. 28, covers cigarettes, e-cigarettes, smokeless tobacco, heated tobacco products and oral nicotine products, including nicotine pouches, the FDA said on Tuesday.

FDA combines two registration forms

Manufacturers previously used Form FDA 3741 for certain tobacco products, including cigarettes and smokeless tobacco, while Form FDA 3741a was used for deemed tobacco products such as e-cigarettes and nicotine pouches.

The redesigned Form FDA 3741 replaces both forms. The FDA said the change eliminates the need for manufacturers to determine which form applies or to complete separate submissions for different product categories.

The new form includes a checklist directing users to sections relevant to their filing. Manufacturers updating an existing registration can also revise specific information without resubmitting sections that have not changed.

The FDA is also encouraging use of a new Form FDA 3741b spreadsheet for initial product list submissions or for adding new products to existing lists.

Existing registrations and product listings will remain in the agency’s Tobacco Registration and Listing Module Next Generation, or TRLM NG. Manufacturers are not required to resubmit their full registration because of the change.

The previous versions of Forms FDA 3741 and 3741a have been retired.

Current requirements remain limited to domestic establishments

The current establishment registration and product listing requirements apply to domestic tobacco product establishments. Domestic manufacturers are required to submit annual establishment registrations by Dec. 31 and update product listings by June 30 and Dec. 31 when specified changes have been made.

The FDA strongly encourages electronic submissions through TRLM NG, although paper submissions remain available.

Separately, the FDA in June proposed extending establishment registration and product listing requirements to foreign tobacco manufacturers.

As 2Firsts reported in June, the proposed rule would require foreign manufacturers to register covered manufacturing establishments and list tobacco products before those products are imported or offered for import into the United States.

The proposal would cover foreign establishments that manufacture, prepare, compound or process FDA-regulated tobacco products. It could include overseas contract manufacturers, OEM and ODM factories, specification developers, bulk product manufacturers and companies involved in repackaging or relabeling.

Foreign manufacturers are not currently subject to the same registration and product listing requirements as domestic establishments. The June proposal has not been finalized.

The FDA said the proposed rule would give it more complete information on foreign-made tobacco products entering the U.S. market and the establishments where they are manufactured, helping the agency identify unauthorized imported products and conduct inspections abroad.

2Firsts View: Manufacturing compliance draws greater attention

Taken together, the latest form update and the FDA’s proposal to bring foreign manufacturers into the registration and product listing system point to a broader regulatory focus on manufacturing establishments and product-level information.

For companies supplying tobacco and nicotine products to the U.S. market, compliance requirements are placing greater emphasis on manufacturing entities and product records, in addition to product authorization and market access.

For further coverage of FDA regulation of tobacco and new tobacco and nicotine products, continue to follow 2Firsts.

Cover image: Screenshot from the FDA website.

2FIRSTS | FDA Proposes Foreign Tobacco Factory Registration Rule to Tighten Import Oversight
2FIRSTS | FDA Proposes Foreign Tobacco Factory Registration Rule to Tighten Import Oversight
The FDA has proposed a rule requiring foreign tobacco manufacturers to register facilities and list products before exporting to the U.S. If finalized, the rule could affect overseas OEM/ODM factories, contract manufacturers, specification developers, bulk product makers, and repackaging or relabeling firms. FDA says the proposal would help identify unauthorized imported tobacco products, including e-cigarettes.
www.2firsts.com


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
The UK’s Vaping Products Duty and Vaping Duty Stamps Scheme will take effect on October 1, 2026. All vaping liquids manufactured in or imported into the UK will face a flat excise duty of £2.20 per 10ml, whether or not they contain nicotine. Newly manufactured or imported products released onto the UK market from October 1 will require a valid duty stamp, while eligible existing unstamped inventory can continue to be sold through March 31, 2027. From April 1, 2027, all vaping products outside duty suspension must carry a valid stamp.
Sep.03
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia's federal government introduced a new illicit tobacco enforcement bill on September 10 that would strengthen evidentiary presumptions, representative sampling, seizure and forfeiture procedures, proceeds-of-crime powers and obligations for customs and logistics operators. The proposal follows the Combatting Illicit Tobacco Act 2026, which took effect in August and increased penalties while expanding investigative and asset-recovery tools. Together, the reforms extend Australia's crackdown from tougher criminal sanctions into import, logistics and evidentiary enforcement.
Sep.14
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06